1

| 2                    | The impact of side effect framing on COVID-19 booster vaccine   |
|----------------------|---|
| 3                    | intentions in an Australian sample.   |
| 4                    | Barnes, K. <sup>1</sup> , Faasse, K. <sup>2</sup> , & Colagiuri, B. <sup>1</sup>  |
| 5                    |   |
| 6                    | <sup>1</sup> School of Psychology, The University of Sydney, Sydney, NSW, Australia   |
| 7                    | <sup>2</sup> School of Psychology, The University of New South Wales, Sydney, NSW, Australia  |
| 8                    |   |
| 9                    |   |
| 10                   |   |
| 11                   |   |
| 12                   |   |
| 13                   |   |
| 14                   |   |
| 15                   |   |
| 16                   |   |
| 17                   |   |
| 18<br>19<br>20<br>21 | Corresponding Author:<br>Dr. Kirsten Barnes,<br>School of Psychology, A18<br>University of Sydney   |
| 22<br>23<br>24       | NSW 2006<br>Australia<br>EmNNE <u>kThis previous reported new research that h</u> as not been certified by peer review and should not be used to guide clinical practice. |

1

| 25 | Abstract  |
|----|---|
| 26 | Objective: To evaluate the effect of presenting positively attribute-framed side effect                     |
| 27 | information on COVID-19 booster vaccine intention relative to standard negatively-framed                    |
| 28 | wording and a no-intervention control.  |
| 29 | <b>Design setting and participants:</b> A representative sample of Australian adults (N=1,204) were         |
| 30 | randomised to one of six conditions within a factorial design: Framing (Positive; Negative;                 |
| 31 | Control) * Vaccine (Familiar (Pfizer); Unfamiliar (Moderna)).   |
| 32 | Intervention: Negative Framing involved presenting the likelihood of experiencing side effects              |
| 33 | (e.g., heart inflammation is very rare, 1 in every 80,000 will be affected), whereas Positive               |
| 34 | Framing involved presenting the same information but as the likelihood of not experiencing side             |
| 35 | effects (e.g., 79,999 in every 80,000 will not be affected).  |
| 36 | Primary Outcome: Booster vaccine intention measured pre- and post-intervention.                             |
| 37 | <b>Results:</b> Positive Framing (M=75.7, SE=0.9, 95% CI[73.9, 77.4]) increased vaccine intention           |
| 38 | relative to Negative Framing (M=70.7, SE=0.9, 95% CI[68.9, 72.4]) overall (F(1, 1192)=4.68,                 |
| 39 | $p=.031$ , $\eta_p^2=.004$ ). Framing interacted with Vaccine and Baseline Intention ( $F(2, 1192)=6.18$ ,  |
| 40 | <i>p</i> =.002, $\eta_p^2$ =.01). Positive Framing was superior, or at least equal, to Negative Framing and |
| 41 | Control at increasing Booster Intention, irrespective of the participants pre-intervention level of         |
| 42 | intent. Side effect worry and perceived severity mediated the effect of Positive vs. Negative               |
| 43 | Framing across vaccines.  |
| 44 | Conclusion: Positive framing of side effect information appears superior for increasing vaccine             |
| 45 | intent relative to the standard negative wording currently used.  |

46 **Pre-registration:** See: aspredicted.org/LDX\_2ZL

2

| 4/ |  |
|----|--|
|    |  |

### Introduction

| 48 | Reasons for vaccine hesitancy are multifaceted <sup>1,2</sup> . However, side effect apprehension is a           |
|----|--|
| 49 | primary factor <sup>1</sup> , with previous experience of COVID-19 vaccine side effects shown to reduce          |
| 50 | later booster vaccine intention <sup>3</sup> . To achieve effective societal protection from COVID-19,           |
|    | -  |
| 51 | behavioural intervention is required to reduce apprehension and increase vaccine acceptance <sup>4</sup> .       |
| 52 | Side effect information framing has been suggested as such an intervention <sup>5</sup> . Standard               |
| 53 | negative wording is typically used to present side effect information on official sources such as                |
| 54 | the Australian Government and AusVaxSafety (a national vaccine safety system) websites. For                      |
| 55 | example, "33% of people were affected by headaches after their second Pfizer dose". Our                          |
| 56 | research suggests negative wording of this type may increase hesitancy relative to positive                      |
| 57 | wording (i.e., presenting the number not affected) <sup>6</sup> . Further, consistent with prior research        |
| 58 | demonstrating that vaccine relevance or familiarity moderates the effect of framing <sup>7,8</sup> , this effect |
| 59 | was especially pronounced when associated with an unfamiliar vaccine <sup>6</sup> .                              |
| 60 | Updating currently presented side effect information with a positively framed                                    |
| 61 | counterpart is both easy to implement and does not violate patient informed consent (given that                  |
| 62 | statistical information is equivalent to the standard negative form) <sup>9</sup> . As such, framing may be      |
| 63 | particularly well suited to increasing vaccine acceptance. However, in our previous research                     |
| 64 | conducted in a UK sample, framing was applied to side effect frequency bands presented in                        |
| 65 | manufacturer Patient Information Leaflets (PILs). This statistical information is commonly                       |
| 66 | presented in the EU, but not in Australia.   |
| 67 | In the present study, we therefore tested an intervention more similar to current                                |
| 68 | Australian sources of side effect information (such as AusVaxSafety). Information detailing                      |
| 69 | severe side effects (heart inflammation and anaphylaxis <sup>10,11</sup> ) and side effect-induced daily         |
| 70 | disruptions (data from AusVaxSafety) were presented to participants who had received two                         |
| 71 | doses of a COVID-19 vaccine but no booster. This information was presented using the                             |
|    |  |

| 72 | standard negative wording (Negative Framing group), positive wording (Positive Framing                                 |
|----|--|
| 73 | group), or not at all (No-Intervention Control group).   |
| 74 | Pre-registered hypotheses were as follows: 1) being presented with objective side effect                               |
| 75 | information, irrespective of type of framing, would increase Booster Intention relative to                             |
| 76 | Control; 2) Positive Framing would increase Booster Intention relative to Negative Framing; 3)                         |
| 77 | Framing (Positive or Negative) would interact with Vaccine Familiarity, with the effect of                             |
| 78 | Positive Framing on Booster Intention being stronger for a less familiar vaccine (i.e., Moderna                        |
| 79 | relative to Pfizer: at the time of data collection ~10,000,000 doses of Moderna had been                               |
| 80 | administered compared to 38,454,860 doses of Pfizer). Secondary-outcomes were explored as                              |
| 81 | potential mediators of the framing effect <sup>9,12,13</sup> (see Supplementary Materials: S1.1).                      |
| 82 |  |
| 83 | Methods  |
| 84 | Participants   |
| 85 | Participants (N=1,204) were recruited via Pureprofile, an ISO-certified panel provider.                                |
| 86 | Inclusion criteria were: 1) 18+ years of age; 2) residing in Australia; 3) self-reported English                       |
| 87 | fluency; 4) two doses of a COVID-19 vaccine; 5) no booster vaccine. Data were collected                                |
| 88 | between 3 <sup>rd</sup> -13 <sup>th</sup> December 2021, just prior to the Omicron outbreak in Australia. Participants |
| 89 | received \$2 for a 10-minute survey. All procedures in this pre-registered study                                       |
| 90 | (aspredicted.org/LDX_2ZL) were approved by the University of Sydney Human Research                                     |
| 91 | Ethics Committee (reference, 2021/871), and all participants provided informed consent.                                |
| 92 | Reporting is consistent with STROBE guidelines (Supporting Information: S1.2).   |
| 93 | Data Collection  |
| 94 | Data were collected on Pureprofile's inhouse platform. Stratification and randomisation                                |
| 95 | (via random number generation) occurred via inbuilt code. Quotas were set for a minimum                                |
| 96 | N=200 in each experimental condition (details below). All items required a response before                             |

4

| 97  | advancement. Several additional items concerning COVID-19 were collected prior to                |
|-----|--|
| 98  | randomisation for a separate pre-registered study (aspredicted.org/XSS_ZD1).                     |
| 99  | Design   |
| 100 | Participants were stratified by their previous two COVID-19 vaccine doses                        |
| 101 | (2xPfizer/2xAstraZeneca/Combination) and randomised to one of six experimental conditions in     |
| 102 | a 3 (Framing: Positive, Negative, Control) by 2 (Vaccine: Familiar(Pfizer) vs.                   |
| 103 | Unfamiliar(Moderna)) factorial design.   |
| 104 | The primary outcome was COVID-19 Booster Intention post-intervention for the                     |
| 105 | assigned vaccine (either Pfizer or Moderna). The following secondary outcomes were measured      |
| 106 | to test for mediation of the framing effect: 1) Side Effect Worry; 2) Side Effect Severity; 3)   |
| 107 | Booster Protection. Two additional outcomes were measured. The first was Booster Intention       |
| 108 | for the "unassigned" vaccine (for the Framing groups, this was the vaccine for which they        |
| 109 | received no side-effect information; for the Control group, this was simply the other vaccine).  |
| 110 | This was used to explore possible generalisation of the framing effect to the other vaccine. The |
| 111 | second was familiarity with the side effects of the Pfizer and Moderna vaccines measured pre-    |
| 112 | intervention. This was used to confirm that participants' responses reflected the assumed        |
| 113 | Familiarity with each vaccine (i.e., Familiar/Pfizer>Unfamiliar/Moderna). All measures were      |
| 114 | rated on 100-point Visual Analogue Scale (VAS).  |


### 115 Framing Intervention

The intervention occurred in five stages. In stage 1, participants selected whether 'daily disruptions' or 'serious side effects' were their primary vaccination concern. In stage 2, they estimated the percentage of the population they believed would experience six side effects common to both the Pfizer and Moderna vaccine (i.e., local reaction, fatigue, headache, muscle or joint pain, gastrointestinal symptoms, fever) after receiving the framed vaccine. In stage 3, they were shown their responses from stage 2 against veridical percentages from Australian population data (derived from AusVaxSafety; 8<sup>th</sup> November 2021) for 1 minute. Stages 2 and 3

5

123 were performed in order to encourage participants to engage with and process the presented side 124 effect information. The primary components of the intervention occurred in stages 4 and 5. In 125 stage 4, participants viewed framed information (either positive or negative depending on group 126 assignment) in the form of infographics regarding 'daily disruptions' from side effects. In stage 5 this was also done regarding 'serious side effects' (estimates from<sup>10,11</sup>). Stages 4 and 5 were 127 128 displayed for 30 seconds each. The exact order of presentation for stages 4 and 5 depended on 129 the participant's primary concern from stage 1. For example, if they indicated that they were 130 more concerned with 'daily disruptions' then that information was first presented at stage 4. 131 The information presented to the Positive and Negative framing groups differed only in 132 terms of whether this information stated the likelihood of experiencing or not experiencing the 133 described side effect. Those assigned to the Negative Framing group saw 'standard' wording 134 regarding side effects (e.g., Heart Inflammation: occurrence is very rare, 1 in every 80,000 will 135 be affected), while those in the Positive Framing group saw the logical inverse (e.g., occurrence 136 is very rare, 79,999 in every 80,000 will not be affected). Example infographics are displayed in 137 Figure 1 (all infographics presented in S1.4). Framed information was not presented to the 138 Control group. Instead, participants undertook an activity of their choosing for an equivalent 139 intervention duration (2 minutes).

6






- Figure 1: Example materials used to present side effect information to those who received
  Positive Framing of the Unfamiliar vaccine (i.e., Moderna). 1a demonstrates the wording when
  presenting estimated and actual prevalence rates for the six common side effects, 1b concerns
- 144 daily disruptions, and 1c serious adverse events from vaccination.
- 145

### 146 **Procedure**

- Prior to randomisation, all participants provided demographic information, as well as 147 148 vaccine and COVID-19 history (see Supporting Information (S1.3) for survey items). They also 149 completed baseline measures for the primary (Booster Intention) and secondary outcomes, 150 before being assigned to a condition. Please note, Baseline Intention was collected for both 151 vaccines (Pfizer and Moderna). Dependent on randomisation, one of these ratings became the 152 baseline for the framed vaccine, and the other the 'unassigned' vaccine (i.e., to explore 153 generalisation). 154 Following group assignment, framing information (positive or negative) regarding sideeffect likelihood for the assigned vaccine was presented to those in the intervention groups. All 155
- 156 participants subsequently provided post-manipulation ratings for primary and secondary
- 157 outcomes. See Figure 2 for a visual representation of the Procedure.

7



158

Figure 2: Sample size, item wording, and experimental design (example: Unfamiliar/Positive
Frame). Participants provided Baseline Booster Intention ratings for both vaccines (Pfizer and
Moderna). Dependent on randomisation, one became the baseline for the framed vaccine and
the other to explore generalisation of the framing effect (i.e., to unassigned vaccine).
Participants were stratified by previous vaccine and randomised to one of six groups (2\*3
factorial design). Those receiving Positive or Negative Framing underwent a manipulation with
five stages: rating of primary concerns; active estimation of side effects; presentation of
estimated side effects against population data; framed information regarding daily disruptions;

estimated side effects against population data; framed information regarding daily disruptions;
 framed information regarding serious side effects. Pre-registered analysis of all secondary

167 named information regarding serious side effects. Fie-registered allarysis of all second

168 outcomes are presented as Supporting Information (S1.1).

8


# 169 Analysis and Sample

| 170                      | Statistical analysis was performed using R (version 4.1.1). Primary analysis was a  |
|--------------------------|---|
| 171                      | 3(Framing)*2(Vaccine) ANCOVA on post-intervention Booster Intention. Pre-specified  |
| 172                      | orthogonal contrasts were: Contrast1 (Control vs. Framing [Positive and Negative combined]);  |
| 173                      | Contrast2 (Positive vs. Negative). Differences in baseline Booster Intention (the covariate) were   |
| 174                      | observed with Vaccine Familiarity ( $F(1, 1198)=172.49, p<.0001, \eta_p^2=.13$ ). As such, interactions   |
| 175                      | between the covariate and manipulated variables (i.e., Framing and Familiarity) were included   |
| 176                      | in the model, as recommended <sup>14,15</sup> . Mediation using the Lavaan package was performed using  |
| 177                      | the secondary outcomes (Side Effect Worry; Side Effect Severity; Booster Protection).   |
| 178                      | Sample size was calculated via an <i>a priori</i> power analysis (95% power, alpha=.05, effect  |
| 179                      | size $f^2=0.02$ ) for a separate concurrent study run that contained more predictors (N=9), and   |
| 180                      | therefore required more power (see study pre-registration).   |
| 181                      |   |
| 182                      | Results   |
| 107                      |   |
| 183                      | Sample  |
| 183                      | Sample<br>A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion  |
|                          | -   |
| 184                      | A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion  |
| 184<br>185               | A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion criteria, 3 terminated at consent, 296 withdrew before completion, and 138 were excluded on  |
| 184<br>185<br>186        | A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion criteria, 3 terminated at consent, 296 withdrew before completion, and 138 were excluded on pre-registered quality-control criteria (see S1.5). The final sample included 1,204 participants.                              |
| 184<br>185<br>186<br>187 | A total of 2,639 participants expressed interest. Of these, 998 did not meet inclusion<br>criteria, 3 terminated at consent, 296 withdrew before completion, and 138 were excluded on<br>pre-registered quality-control criteria (see S1.5). The final sample included 1,204 participants.<br><b>Demographics</b> |

- 191 Table 1: Sample descriptive statistics presented against population data generated from the
- 192 Australian Bureau of Statistics, Education and Work Dataset 2021. *Nb*: Education sums to
- 193 109% due to calculation relying on separate ISCED and ASCED items to calculates estimates
- 194 for Primary and High School completers. Dashes denote unavailable population data.
- 195

|                                | Control<br>Familiar | Control<br>Unfamiliar | Negative<br>Familiar | Negative<br>Unfamiliar | Positive<br>Familiar | Positive<br>Unfamiliar | All<br>Respondents | Australian<br>population |
|--------------------------------|---------------------|-----------------------|----------------------|------------------------|----------------------|------------------------|--------------------|--------------------------|
|                                | N=201               | N=200                 | N=201                | N=201                  | N=200                | N=201                  | (%)                | (%)                      |
| <b>Demographic Information</b> | 1                   |                       |                      |                        |                      |                        |                    |                          |
| State/territory                |                     |                       |                      |                        |                      |                        |                    |                          |
| New South Wales                | 68                  | 64                    | 62                   | 67                     | 65                   | 53                     | 31.5               | 31.7                     |
| Victoria                       | 48                  | 48                    | 58                   | 52                     | 54                   | 57                     | 26.3               | 26.3                     |
| Queensland                     | 42                  | 42                    | 36                   | 42                     | 37                   | 46                     | 20.3               | 20.0                     |
| Western Australia              | 21                  | 17                    | 16                   | 19                     | 21                   | 27                     | 10.0               | 10.4                     |
| South Australia                | 12                  | 23                    | 16                   | 11                     | 18                   | 10                     | 7.5                | 6.9                      |
| Tasmania                       | 5                   | 0                     | 8                    | 4                      | 6                    | 3                      | 2.2                | 2.1                      |
| Australian Capital             | 5                   | 4                     | 4                    | 5                      | 2                    | 2                      | 1.8                | 1.7                      |
| Territory                      | č                   | ·                     | •                    | e                      | -                    | -                      | 1.0                | 1.,                      |
| Northern Territory             | 0                   | 2                     | 1                    | 1                      | 0                    | 0                      | 0.3                | 0.8                      |
| Region                         | U U                 | -                     | 1                    | 1                      | Ū                    | v                      | 0.5                | 0.0                      |
| Metro                          | 153                 | 147                   | 147                  | 147                    | 129                  | 140                    | 71.7               | 67.7                     |
| Regional                       | 48                  | 53                    | 54                   | 54                     | 71                   | 61                     | 28.3               | 32.3                     |
| <i>Employment</i>              | 40                  | 55                    | 54                   | J <del>4</del>         | / 1                  | 01                     | 20.3               | 32.5                     |
|                                | 05                  | 70                    | 00                   | 00                     | 70                   | 07                     | 11 5               | 40.4                     |
| Employed full-time             | 85                  | 79                    | 88                   | 88                     | 78<br>25             | 82                     | 41.5               | 49.4                     |
| Employed part-time             | 40                  | 47                    | 35                   | 36                     | 35                   | 31                     | 18.6               | 21.7                     |
| Self employed                  | 6                   | 9                     | 5                    | 9                      | 9                    | 8                      | 3.8                | -                        |
| Unemployed (looking)           | 9                   | 9                     | 10                   | 13                     | 7                    | 14                     | 5.1                | 1.3                      |
| Carer                          | 12                  | 10                    | 7                    | 12                     | 14                   | 13                     | 5.6                | -                        |
| Student                        | 4                   | 9                     | 9                    | 6                      | 9                    | 6                      | 3.6                | -                        |
| Retired                        | 44                  | 37                    | 45                   | 37                     | 47                   | 46                     | 21.3               | -                        |
| Other                          | 1                   | 0                     | 2                    | 0                      | 1                    | 1                      | 0.4                | -                        |
| Education                      |                     |                       |                      |                        |                      |                        |                    |                          |
| Primary school                 | 1                   | 0                     | 0                    | 1                      | 2                    | 0                      | 0.3                | 4.5                      |
| High school                    | 51                  | 58                    | 46                   | 53                     | 57                   | 60                     | 27.0               | 45.2                     |
| Technical certificate          | 28                  | 30                    | 34                   | 29                     | 29                   | 34                     | 15.3               | 18.5                     |
| Advanced                       | 25                  | 26                    | 41                   | 20                     | 25                   | 23                     | 13.3               | 10.1                     |
| diploma/diploma                |                     |                       |                      |                        |                      |                        |                    |                          |
| Bachelor's degree              | 59                  | 40                    | 48                   | 59                     | 51                   | 49                     | 25.4               | 20.6                     |
| Graduate                       | 14                  | 16                    | 11                   | 13                     | 12                   | 16                     | 6.8                | 10.1                     |
| diploma/certificate            |                     | - •                   |                      |                        |                      | ••                     | 0.0                |                          |
| Postgraduate                   | 22                  | 29                    | 21                   | 24                     | 23                   | 19                     | 11.5               | 8.5                      |
| Other                          | 1                   | 1                     | 0                    | 2                      | 1                    | 0                      | 0.4                | -                        |
| Country of Birth               | 1                   | 1                     | U                    | 2                      | 1                    | U                      | U.T                | -                        |
| Australia                      | 151                 | 152                   | 156                  | 167                    | 160                  | 162                    | 78.7               | 65.6                     |
| Overseas                       | 50                  | 48                    | 45                   | 34                     | 40                   | 39                     | 28.3               | 34.4                     |
| Gender                         | 50                  | 40                    | 45                   | 34                     | 40                   | 37                     | 20.3               | 34.4                     |
|                                | 102                 | 00                    | 0.4                  | 102                    | 106                  | 104                    | 50.5               | 50 7                     |
| Woman                          | 103                 | 99<br>101             | 94<br>105            | 102                    | 106                  | 104                    | 50.5               | 50.7                     |
| Man                            | 98                  | 101                   | 105                  | 99                     | 94                   | 97                     | 49.3               | 49.3                     |
| Non-binary / other             | 0                   | 0                     | 2                    | 0                      | 0                    | 0                      | 0.2                | -                        |
| Age bracket (years)            |                     |                       |                      |                        |                      |                        |                    |                          |
| 18-24                          | 20                  | 24                    | 20                   | 22                     | 21                   | 19                     | 10.5               | 12.1                     |
| 25-34                          | 33                  | 39                    | 51                   | 42                     | 37                   | 35                     | 19.7               | 20.6                     |
| 35-44                          | 39                  | 41                    | 27                   | 38                     | 33                   | 32                     | 17.4               | 19.3                     |
| 45-54                          | 36                  | 29                    | 30                   | 33                     | 37                   | 37                     | 16.8               | 18.0                     |
| 55-64                          | 28                  | 29                    | 31                   | 25                     | 36                   | 30                     | 14.9               | 16.6                     |
| 65+                            | 45                  | 38                    | 42                   | 41                     | 36                   | 48                     | 20.8               | 13.3                     |
| Vaccine / COVID-19 Histo       | ory                 |                       |                      |                        |                      |                        |                    |                          |
| Previous COVID-19 Vaccin       | •                   |                       |                      |                        |                      |                        |                    |                          |
| AstraZeneca (both              | 84                  | 84                    | 84                   | 84                     | 83                   | 84                     | 41.8               | -                        |
| doses)                         | -                   | -                     | -                    | -                      |                      | -                      | -                  |                          |
| <b>d</b> 05 <b>0</b> 5)        |                     |                       |                      |                        |                      |                        |                    |                          |

|                                      |                |                      |     |     |     |     | 10   |  |
|--------------------------------------|----------------|----------------------|-----|-----|-----|-----|------|--|
| Pfizer (both doses)                  | 116            | 115                  | 116 | 116 | 116 | 115 | 57.6 |  |
| AstraZeneca and Pfizer (combination) | 1              | 1                    | 1   | 1   | 1   | 2   | 06   |  |
| Months since last COVID              | -19 vaccinati  | on                   |     |     |     |     |      |  |
| 0-5                                  | 188            | 185                  | 183 | 176 | 185 | 180 | 91.1 |  |
| 6-15                                 | 12             | 13                   | 15  | 22  | 12  | 19  | 7.7  |  |
| 16-20                                | 1              | 2                    | 3   | 3   | 3   | 2   | 1.2  |  |
| COVID-19 Exposure: Per               | sonal infectio | on                   |     |     |     |     |      |  |
| Yes                                  | 7              | 4                    | 5   | 2   | 6   | 3   | 2.2  |  |
| No                                   | 194            | 196                  | 196 | 199 | 194 | 198 | 97.8 |  |
| COVID-19 Exposure: Sig               | nificant othe  | rs                   |     |     |     |     |      |  |
| Yes                                  | 28             | 24                   | 24  | 25  | 21  | 24  | 12.1 |  |
| No                                   | 173            | 176                  | 177 | 176 | 197 | 177 | 89.4 |  |
| Previously heard of the P            | fizer COVID-   | 19 vaccine           |     |     |     |     |      |  |
| Yes                                  | 198            | 198                  | 198 | 196 | 198 | 200 | 98.7 |  |
| No                                   | 3              | 2                    | 3   | 5   | 2   | 1   | 1.3  |  |
| Previous heard of the Mo             | derna COVIL    | <b>D-</b> 19 vaccine |     |     |     |     |      |  |
| Yes                                  | 183            | 185                  | 181 | 178 | 174 | 187 | 90.4 |  |
| No                                   | 18             | 15                   | 20  | 23  | 26  | 14  | 9.6  |  |
| <u> </u>                             |                |                      |     |     |     |     |      |  |



197

- 200201Manipulation Checks
- 202 As expected, side effect familiarity was greater for the Pfizer than Moderna vaccine
- 203  $(t(1203)=28.63, p<.0001, \text{Cohen's } d_z =.83)$ . During the intervention, more participants

<sup>198</sup> Figure 3: Geospatial data with participant frequency plotted against SA4 postal regions in199 Australia

| 204  | underestimated side effects for the Modena (N=118) relative to Pfizer (N=65) vaccine ( $\chi^2(1) =$   |
|--|--|
| 205  | 18.97, $p \le .0001$ ), due to the vaccine having a higher incidence of side effects than Pfizer.  |
| 206  | Primary Analysis   |
| 207  | Booster Intentions were higher for any Framing relative to Control (Contrast1: $F(1, $   |
| 208  | 1192)=11.56, <i>p</i> =.0007, $\eta_p^2$ =.010) and for Positive Framing ( <i>M</i> =75.7, <i>SE</i> =0.9, 95% CIs[73.9,   |
| 209  | 77.4]) relative to Negative Framing ( <i>M</i> =70.7, <i>SE</i> =0.9, 95% CIs[68.9, 72.4]; <i>F</i> (1, 1192)=4.68,  |
| 210  | <i>p</i> =.031, $\eta_p^2$ =.004). As presented in Figure 4a, the anticipated Framing*Vaccine interaction was  |
| 211  | not significant at Contrast2 (Positive vs. Negative: $F(1, 1192)=3.31$ , $p=.069$ , $\eta_p^2=.003$ ), but was   |
| 212  | at Contrast1 (Framing vs. Control: $F(1, 1192)=8.91, p=.003, \eta_p^2=.007$ ), with the effect of any  |
| 213  | information over Control larger for the Unfamiliar vaccine (see S1.6 for full model output and   |
|  |  |
| 214  | means).  |
| 214<br>215   | means).<br>As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was   |
|  |  |
| 215  | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was  |
| 215<br>216   | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was present at both Contrasts (Control vs. Framing: $F(1, 1192)=7.39$ , $p=.007$ , $\eta_p^2=.006$   Positive vs.  |
| <ul><li>215</li><li>216</li><li>217</li></ul>  | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was<br>present at both Contrasts (Control vs. Framing: $F(1, 1192)=7.39$ , $p=.007$ , $\eta_p^2=.006$   Positive vs.<br>Negative: $F(2, 1192)=5.26$ , $p=.022$ , $\eta_p^2=.004$ ). For the less familiar Moderna vaccine, Positive  |
| <ul><li>215</li><li>216</li><li>217</li><li>218</li></ul>                                | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was<br>present at both Contrasts (Control vs. Framing: $F(1, 1192)=7.39$ , $p=.007$ , $\eta_p^2=.006$   Positive vs.<br>Negative: $F(2, 1192)=5.26$ , $p=.022$ , $\eta_p^2=.004$ ). For the less familiar Moderna vaccine, Positive<br>Framing ( $M=94.92$ , $SE=1.88$ , 95% CI[91.24, 98.60]) increased Booster Intention relative to   |
| <ul> <li>215</li> <li>216</li> <li>217</li> <li>218</li> <li>219</li> </ul>              | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was<br>present at both Contrasts (Control vs. Framing: $F(1, 1192)=7.39$ , $p=.007$ , $\eta_p^2=.006$   Positive vs.<br>Negative: $F(2, 1192)=5.26$ , $p=.022$ , $\eta_p^2=.004$ ). For the less familiar Moderna vaccine, Positive<br>Framing ( $M=94.92$ , $SE=1.88$ , 95% CI[91.24, 98.60]) increased Booster Intention relative to<br>Negative Framing ( $M=87.18$ , $SE=1.95$ , 95% CI[83.35, 91.0]) at high Baseline Intent  |
| <ul> <li>215</li> <li>216</li> <li>217</li> <li>218</li> <li>219</li> <li>220</li> </ul> | As in Figure 4b, a three-way Framing*Vaccine*Baseline Intention interaction was<br>present at both Contrasts (Control vs. Framing: $F(1, 1192)=7.39$ , $p=.007$ , $\eta_p^2=.006$   Positive vs.<br>Negative: $F(2, 1192)=5.26$ , $p=.022$ , $\eta_p^2=.004$ ). For the less familiar Moderna vaccine, Positive<br>Framing ( $M=94.92$ , $SE=1.88$ , 95% CI[91.24, 98.60]) increased Booster Intention relative to<br>Negative Framing ( $M=87.18$ , $SE=1.95$ , 95% CI[83.35, 91.0]) at high Baseline Intent<br>(VAS=100). For the more familiar Pfizer vaccine, Positive Framing ( $M=24.03$ , $SE=4.29$ , 95% |




Figure 4: Model estimated mean differences in the primary outcome (Booster Intention). 4a depicts mean Booster Intention for each framing condition by vaccine type. 4b depicts the

227 Framing\*Familiarity\*Baseline Booster Intention interaction. All error bars represent  $\pm 1$ SEM.

228 229

# Secondary-Predictors: Mediation

230 Positive Framing is theorised to create a valence-consistent shift in perceptions that 231 alters evaluation and intention<sup>16,17</sup>. Analysis was therefore run to explore whether side effect perceptions mediated the effect of framing (Positive vs. Negative) on Booster Intentions across 232 233 vaccines (i.e., as if the intervention were generally applied). Three models were run with 234 baseline-corrected Booster Intention (change score) as the outcome and baseline-corrected 235 secondary predictors as mediators. As in Table 2, partial mediation was observed through a 236 decrease in Side Effect Worry and Severity associated with Positive Framing. This was specific 237 to side effect perceptions and not significant for Booster Protection.

238

13

| 239 | Table 2: Mediation of Framing (Positive vs. Negative) on Booster Intention through Side Effect    |
|-----|---|
| 240 | Worry, Perception of Side Effect Severity, and Perceived Booster Protection. Paths a and b        |
| 241 | represent paths from predictor to mediator and mediator to outcome. Path c represents the total   |
| 242 | effect (Framing on Booster Intention), c' the association between Framing and Booster Intention   |
| 243 | controlling for all other paths, and a*b indirect effect of the mediator on the Framing – Booster |
| 244 | Intention association. Bias-corrected bootstrapped 95% CIs (10,000 samples) are presented.        |
| 245 |   |

|     | β     | В     | SE B | Ζ     | р     | 95% CIs        |
|-----|-------|-------|------|-------|-------|----------------|
| а   | -0.14 | -6.51 | 1.66 | -3.92 | <.001 | [-9.85, -3.36] |
| b   | -0.18 | -0.15 | 0.04 | -3.77 | <.001 | [-0.18, -0.18] |
| с   | 0.10  | 3.93  | 1.37 | 2.87  | .004  | [1.22, 6.55]   |
| c'  | 0.08  | 2.98  | 1.34 | 2.23  | .026  | [0.33, 5.56]   |
| a*b | 0.02  | 0.95  | 0.35 | 2.68  | .007  | [0.40, 1.82]   |

A) Mediation Model: Side Effect Worry

| B) | Mediation | Model: | Perceived | Side | Effect | Severity |
|----|-----------|--------|-----------|------|--------|----------|
|----|-----------|--------|-----------|------|--------|----------|

|     | β     | В     | SE B | Ζ     | р     | 95% CIs         |
|-----|-------|-------|------|-------|-------|-----------------|
| а   | -0.20 | -8.63 | 1.48 | -5.83 | <.001 | [-11.54, -5.66] |
| b   | -0.20 | -0.18 | 0.05 | -3.67 | <.001 | [-0.29, -0.09]  |
| c   | 0.10  | 3.93  | 1.37 | 2.87  | .004  | [1.22, 6.55]    |
| c'  | 0.06  | 2.34  | 1.37 | 1.71  | .088  | [-0.36, 4.99]   |
| a*b | 0.04  | 1.59  | 0.52 | 3.02  | .002  | [0.04, 0.08]    |

C) Mediation Model: Perceived Booster Protection

|     | β    | В    | SE B | Ζ    | р     | 95% CIs       |
|-----|------|------|------|------|-------|---------------|
| а   | 0.05 | 1.74 | 1.16 | 1.50 | .134  | [-0.53, 3.99] |
| b   | 0.32 | 0.38 | 0.06 | 5.88 | <.001 | [0.25, 0.50]  |
| c   | 0.10 | 3.93 | 1.37 | 1.47 | .004  | [1.22, 6.55]  |
| c'  | 0.09 | 3.28 | 1.30 | 2.52 | .012  | [0.70, 5.75]  |
| a*b | 0.02 | 0.66 | 0.45 | 1.47 | .143  | [-0.15, 1.62] |

<sup>246</sup> 

247

248

### Discussion

| 249 | The present study tested an intervention involving the presentation of framed side-effect                     |
|-----|---|
| 250 | information. Overall, providing side effect information of any type to participants increased                 |
| 251 | their COVID-19 Booster Intention relative to the Control group, who received no information at                |
| 252 | all. Of note, Positive Framing further increased Booster Intention relative to Negative Framing               |
| 253 | by 5 percentage points. While the mapping between intention and uptake is unlikely to be                      |
| 254 | exact <sup>18</sup> (see below), our results suggest that Positive Framing could lead to up to half a million |

14

| 255 | extra booster vaccinations among those aged 18 and over (based on population averages from                |
|-----|---|
| 256 | the ABS Education and Work Dataset 2021). Results therefore indicate that presenting                      |
| 257 | positively-framed information to people, for example on Australian Government and                         |
| 258 | AusVaxSafety websites, is likely to increase favorable perceptions of booster vaccination.                |
| 259 | Based on our previous research <sup>6</sup> and the broader literature concerning framing effects on      |
| 260 | vaccine-related intentions <sup>7,8</sup> , vaccine familiarity was anticipated to modulate the effect of |
| 261 | Positive Framing. However, Booster Intention after Positive Framing was only numerically, not             |
| 262 | statistically, larger for the less familiar Moderna vaccine compared to Negative Framing.                 |
| 263 | Instead, we found that both Positive and Negative provided an increased benefit to Booster                |
| 264 | Intention over Control for the less familiar Moderna vaccine relative to the more familiar Pfizer         |
| 265 | vaccine (although this appeared to be driven by the Positive Framing manipulation). A three-              |
| 266 | way interaction involving Baseline Intention qualified these effects. Here, the difference                |
| 267 | between Positive and Negative Framing was largest at low levels of Baseline Intent for the                |
| 268 | Familiar vaccine, but at high levels of Baseline Intent for the Unfamiliar vaccine. In our                |
| 269 | previous research, Positive Framing was found to decrease Booster Intention relative to                   |
| 270 | Negative Framing for familiar vaccines <sup>6</sup> . Notably, this was not the case here. Several        |
| 271 | differences exist between these studies, such as sample location, number of framed side effects,          |
| 272 | and the mode of presentation (PILs vs. infographics). As such, future research should strive to           |
| 273 | understand the conditions under which Positive Framing reduces vaccine intention to ensure that           |
| 274 | optimal messaging is employed.  |
| 275 | Population level public health information on side effects is inherently general and                      |

Population level public health information on side effects is inherently general and
cannot contain nuanced information about the influence of prior history of vaccination or
hesitancy. While a complex pattern of results was observed, Positive Framing was always either
superior, or equal to, Negative Framing and Control at all levels of Baseline Intent for both
vaccines. Moreover, at differing levels of Baseline Intent, Negative Framing decreased Booster
Intention relative to Positive Framing for both familiar and less familiar vaccines. Among those

15

281 most resistant to vaccination, Positive Framing of the more familiar vaccine (Pfizer) increased 282 Booster Intention by 14.6 percentage-points relative to Negative Framing, and by 19.8 283 percentage-points relative to Control for the less familiar vaccine (Moderna). As such, there was 284 never any disadvantage to employing Positive Framing in the present sample, even when 285 targeting those with low Baseline Intent; a population where increasing vaccine acceptance is of critical importance<sup>19</sup>. This suggests that Positive Framing is the optimal presentation mode. 286 287 In terms of mechanisms, theories of attribute framing posit that Positive Framing results in a valence-consistent shift in perception that alters evaluation<sup>16,17</sup>. We therefore reasoned that 288 289 Positive Framing would alter side effect perception, increasing intention to be vaccinated. 290 Mediation analysis provided tentative support for this theory. Specifically, a reduction in the 291 perception of side effect severity and side effect worry partially mediated the effect of Positive 292 (vs. Negative) Framing on Booster Intention, suggesting that Framing may indeed reduce side 293 effect hesitancy. Mediation was not found through perceived booster protection, with the 294 association between Framing and booster protection weaker than with side effect perceptions 295 (severity and worry).

296 There are several strengths to the present study, including the framing of real COVID-19 297 vaccines and the use of actual side effect data presented to the Australian population. Especially 298 as much of the literature in this area frames fictitious vaccines and asks participants to imagine scenarios that they have never experienced and may be unlikely to ever experience<sup>7,8,12,17,20</sup>. 299 300 Limitations of the study include the measurement of intention, but not uptake. While intention 301 has been found to predict vaccination<sup>21-24</sup>, longitudinal research is needed to directly assess the 302 role of framing on actual uptake, as well as the longevity of the framing effect among those yet to receive a booster vaccine. Relevant to the lag in booster uptake in Australia<sup>25</sup>, the present 303 304 research focused on increasing intention among those already receiving a primary course of 305 COVID-19 vaccination. However, these results do not speak to the effect of framing on those 306 never vaccinated. Investigation of framing on vaccine intention at all points of the vaccination

307 programme would provide a more comprehensive account of the effect of framing on vaccine

308 intentions in general.

| 309 | In summary, a brief online intervention engaging participants in side effect estimation                    |
|-----|--|
| 310 | before presenting positively framed side effect information can increase booster vaccine                   |
| 311 | intention. Given the ease with which Positive Framing can be implemented, combined with the                |
| 312 | fact that the presentation of statistical information in this format does not violate patient              |
| 313 | informed consent <sup>9</sup> , the potential exists for framing of this type to make a real difference in |
| 314 | improving societal protection from COVID-19 through reduced vaccine hesitancy.                             |

- 315 **Sources of Funding**: This research was supported by Australian Research Council grants
- 316 DP180102061 and DP200101748. The funding body had no involvement in study design,
- 317 analysis, interpretation, writing, or the decision to submit the present article for publication.
- 318
- 319 Data Availability: The code and raw data necessary to replicate the reported analysis is
- 320 available through the Open Science Framework repository:
- 321 <u>https://osf.io/nfxr3/?view\_only=e0717d3f063245268f8ce88144afaa3f</u>
- 322
- 323 Author contributions: KB, BC and KF conceived the experimental design. KB was
- 324 responsible for collecting and analysing the data. KB wrote the first draft of the article. BC and
- 325 KF edited and contributed to the final version.

18

| 327 |    | References   |
|-----|----|--|
| 328 | 1  | Solís Arce, J. S. et al. COVID-19 vaccine acceptance and hesitancy in low- and middle- |
| 329 |    | income countries. Nature Medicine 27, 1385-1394 (2021).                                |
| 330 | 2  | Troiano, G. & Nardi, A. Vaccine hesitancy in the era of COVID-19. Public Health 194,   |
| 331 |    | 245-251 (2021).  |
| 332 | 3  | Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19    |
| 333 |    | Vaccine Dose in Poland. Vaccines 9, 1286 (2021).                                       |
| 334 | 4  | Chevallier, C., Hacquin, AS. & Mercier, H. COVID-19 Vaccine Hesitancy: Shortening      |
| 335 |    | the Last Mile. Trends in Cognitive Sciences 25, 331-333 (2021).                        |
| 336 | 5  | World Health Organization. Data for action: achieving high uptake of COVID-19          |
| 337 |    | vaccines: gathering and using data on the behavioural and social drivers of            |
| 338 |    | vaccination: a guidebook for immunization programmes and implementing partners:        |
| 339 |    | interim guidance, 1 April 2021. (World Health Organization, Geneva, 2021);             |
| 340 |    | https://apps.who.int/iris/handle/10665/340645  |
| 341 | 6  | Barnes, K. & Colagiuri, B. Positive attribute framing increases COVID-19 booster       |
| 342 |    | vaccine intention for unfamiliar vaccines. Preprint at:                                |
| 343 |    | https://www.medrxiv.org/content/10.1101/2022.01.25.22269855v2 (2022).                  |
| 344 | 7  | Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant  |
| 345 |    | Immunization: The Influence of Involvement. Health Education & Behavior 27, 82-95      |
| 346 |    | (2000).  |
| 347 | 8  | Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within     |
| 348 |    | messages to change vaccination behavior. Journal of Communication in Healthcare 8,     |
| 349 |    | 45-54 (2015).  |
| 350 | 9  | Barnes, K. et al. Can Positive Framing Reduce Nocebo Side Effects? Current Evidence    |
| 351 |    | and Recommendation for Future Research. Frontiers in Pharmacology 10, 167 (2019).      |
| 352 | 10 | Shimabukuro, T. T., Cole, M. & Su, J. R. Reports of Anaphylaxis After Receipt of       |
| 353 |    | mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA              |
| 354 |    | <b>325</b> (11), 1101–1102 (2021).   |
| 355 | 11 | Diaz, G. A. et al. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA   |
| 356 |    | <b>326</b> (12), 1210–1212 (2021).   |
| 357 | 12 | Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two |
| 358 |    | Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A     |
| 359 |    | Randomised Trial of 16- to 75-Year-Olds in England. Drug Safety 43, 1011–1022          |
| 360 |    | (2020).  |

| 361 | 13 | Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:  |
|-----|----|---|
| 362 |    | An empirical evaluation of EU recommended terminology. Psychology, Health &             |
| 363 |    | Medicine 8, 251-263 (2003).   |
| 364 | 14 | Myers, J. L. & Well, A. D. Research design and statistical analysis, 2nd ed. (Lawrence  |
| 365 |    | Erlbaum Associates Publishers, 2003).   |
| 366 | 15 | Cardinal, R. N. & Aitken, M. R. F. ANOVA for the behavioural sciences researcher.       |
| 367 |    | (Lawrence Erlbaum Associates Publishers, 2006).   |
| 368 | 16 | Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A       |
| 369 |    | Typology and Critical Analysis of Framing Effects. Organizational Behavior and          |
| 370 |    | Human Decision Processes 76, 149-188 (1998).  |
| 371 | 17 | Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in |
| 372 |    | Health Decisions. Organizational Behavior and Human Decision Processes 85, 382-399      |
| 373 |    | (2001).   |
| 374 | 18 | Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.            |
| 375 |    | European Review of Social Psychology 12, 1-36 (2002).                                   |
| 376 | 19 | Ten threats to global health in 2019 (World Health Organisation, 2019);                 |
| 377 |    | https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019            |
| 378 | 20 | Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of            |
| 379 |    | recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in            |
| 380 |    | hypothetical patient scenarios. Breast Cancer Research and Treatment 60, 9-14 (2000).   |
| 381 | 21 | Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in       |
| 382 |    | Young Adult Women: Comparing the Health Belief Model and Theory of Planned              |
| 383 |    | Behavior. Annals of Behavioral Medicine 44, 171-180 (2012).                             |
| 384 | 22 | Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:    |
| 385 |    | Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual     |
| 386 |    | Vaccination Behavior? Women's Health Issues 21, 71-79 (2011).                           |
| 387 | 23 | Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get            |
| 388 |    | vaccinated against influenza and actual vaccination uptake of Dutch healthcare          |
| 389 |    | personnel. Vaccine 32, 6986-6991 (2014).  |
| 390 | 24 | Jensen, U. T., Ayers, S. & Koskan, A. M. Video-based messages to reduce COVID-19        |
| 391 |    | vaccine hesitancy and nudge vaccination intentions. PLOS ONE, 17(4) e0265736            |
| 392 |    | (2022).   |
| 393 | 25 | Nicholas, J. Tracking Australia's booster rollout: data shows millions of eligible      |
| 394 |    | Australians yet to get third Covid vaccine dose. The Guardian (Australia) 2022; 17      |

| 395 | March. https://www.theguardian.com/australia-news/australia-                     |
|-----|--|
| 396 | datablog/2022/mar/17/tracking-australias-booster-rollout-data-shows-millions-of- |

397 <u>eligible-australians-yet-to-get-third-covid-vaccine-dose</u> (accessed March 2022).